112 related articles for article (PubMed ID: 15787802)
1. Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy.
Al-Akash SI; Al Makadma AS; Al Omari MG
Pediatr Transplant; 2005 Apr; 9(2):249-53. PubMed ID: 15787802
[TBL] [Abstract][Full Text] [Related]
2. Low viral load post-transplant lymphoproliferative disease localized within the tongue.
Henry DD; Hunger SP; Braylan RC; Dharnidharka VR
Transpl Infect Dis; 2008 Dec; 10(6):426-30. PubMed ID: 18657087
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma.
Jiménez-Rivera C; Avitzur Y; Fecteau AH; Jones N; Grant D; Ng VL
Pediatr Transplant; 2004 Jun; 8(3):243-8. PubMed ID: 15176961
[TBL] [Abstract][Full Text] [Related]
4. Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child.
Hayashida M; Ogita K; Matsuura T; Takahashi Y; Nishimoto Y; Ohga S; Hara T; Soejima Y; Taketomi A; Maehara Y; Kohashi K; Tsuneyoshi M; Taguchi T
Pediatr Transplant; 2007 Sep; 11(6):671-5. PubMed ID: 17663692
[TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.
Garcia VD; Bonamigo Filho JL; Neumann J; Fogliatto L; Geiger AM; Garcia CD; Barros V; Keitel E; Bittar AE; Ferrera des Santos A; Roithmann S
Transpl Int; 2003 Mar; 16(3):202-6. PubMed ID: 12664217
[TBL] [Abstract][Full Text] [Related]
7. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
Knoop C; Kentos A; Remmelink M; Garbar C; Goldman S; Feremans W; Estenne M
Clin Transplant; 2006; 20(2):179-87. PubMed ID: 16640524
[TBL] [Abstract][Full Text] [Related]
8. Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus.
Kaposztas Z; Etheridge WB; Kahan BD
Transplant Proc; 2008 Jun; 40(5):1744-6. PubMed ID: 18589184
[TBL] [Abstract][Full Text] [Related]
9. Novel treatment with rituximab of oropharyngeal posttransplant lymphoproliferative disorder after heart transplantation.
Kaczmarek I; Beiras-Fernandez A; Sadoni S; Bengel D; Deutsch MA; Meiser B; Reichart B
Exp Clin Transplant; 2005 Dec; 3(2):381-4. PubMed ID: 16417448
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus in pediatric liver transplantation: a single-center experience.
Gibelli NE; Tannuri U; Pinho-Apezzato ML; Tannuri AC; Maksoud-Filho JG; Andrade WC; Velhote MC; Santos MM; Ayoub AA; Marques da Silva M
Transplant Proc; 2009 Apr; 41(3):901-3. PubMed ID: 19376384
[TBL] [Abstract][Full Text] [Related]
11. Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient.
Dharnidharka VR; Douglas VK; Hunger SP; Fennell RS
Pediatr Transplant; 2004 Feb; 8(1):87-90. PubMed ID: 15009846
[TBL] [Abstract][Full Text] [Related]
12. Rituximab for post-transplant recurrences of FSGS.
Bayrakci US; Baskin E; Sakalli H; Karakayali H; Haberal M
Pediatr Transplant; 2009 Mar; 13(2):240-3. PubMed ID: 18822107
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
[TBL] [Abstract][Full Text] [Related]
14. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation.
Cornejo A; Bohnenblust M; Harris C; Abrahamian GA
Cancer Chemother Pharmacol; 2009 Sep; 64(4):857-60. PubMed ID: 19588139
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder.
Cullis B; D'Souza R; McCullagh P; Harries S; Nicholls A; Lee R; Bingham C
Am J Kidney Dis; 2006 May; 47(5):e67-72. PubMed ID: 16632009
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
Garceau P; Couture C; Cantin B; Bernier V; Sénéchal M
J Heart Lung Transplant; 2008 Aug; 27(8):928-31. PubMed ID: 18656811
[TBL] [Abstract][Full Text] [Related]
17. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus in pediatric patients: results in the first 6 months post-renal transplant.
Hymes LC; Warshaw BL
Pediatr Transplant; 2005 Aug; 9(4):520-2. PubMed ID: 16048606
[TBL] [Abstract][Full Text] [Related]
19. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
Svoboda J; Kotloff R; Tsai DE
Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
[TBL] [Abstract][Full Text] [Related]
20. Long-term maintenance therapy for post-cardiac transplant monoclonal lymphoproliferative disorder: caveat mammalian target of rapamycin.
Khalpey Z; Miller DV; Schmitto JD; Kushwaha SS
Transplant Proc; 2011 Jun; 43(5):1893-9. PubMed ID: 21693296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
